$SAVA
CASSAVA SCIENCES INC Stock $sava

$sava Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000143774923030502 Filed on November 07, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.058M	$4.280M	$2.819M
YoY Change	23.53%	51.83%	64.66%
% of Gross Profit
Research & Development	$18.73M	$23.60M	$18.53M
YoY Change	6.11%	27.4%
% of Gross Profit
Depreciation & Amortization	$356.0K	$273.0K	$181.0K
YoY Change	-8.48%	50.83%	-14.62%
% of Gross Profit
Operating Expenses	$22.79M	$27.88M	$21.35M
YoY Change	8.85%	30.61%	118.86%
Operating Profit		-$27.88M	-$21.35M
YoY Change		30.61%	118.86%
Interest Expense	$1.579M	$2.005M	$878.0K
YoY Change	1.61%	128.36%	5753.33%
% of Operating Profit
Other Income/Expense, Net	$291.0K	$223.0K	$210.0K
YoY Change	16.87%	6.19%	19.32%
Pretax Income	-$20.92M	-$25.65M	-$20.26M
YoY Change	9.33%	26.62%	111.85%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$20.92M	-$25.65M	-$20.26M
YoY Change	9.33%	26.63%	111.85%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.61	-$0.51
Diluted Earnings Per Share	-$0.50	-$0.61	-$505.8K
COMMON SHARES
Basic Shares Outstanding	42.17M	41.97M	40.10M
Diluted Shares Outstanding		42.00M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$121.1M	$142.4M	$174.7M
YoY Change	-39.74%	-18.47%	-27.68%
Cash & Equivalents	$121.1M	$142.4M	$174.7M
Short-Term Investments
Other Short-Term Assets	$287.0K	$189.0K	$8.610M
YoY Change	-97.19%	-97.8%	-17.14%
Inventory
Prepaid Expenses
Receivables	$962.0K	$1.300M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$129.6M	$150.2M	$183.3M
YoY Change	-38.63%	-18.05%	-27.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.85M	$22.08M	$23.13M
YoY Change	-4.42%	-4.55%	11.77%
Goodwill
YoY Change
Intangibles	$176.0K	$268.0K	$740.0K
YoY Change	-71.7%	-63.78%	-38.79%
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$22.03M	$22.35M	$24.01M
YoY Change	-6.68%	-6.95%	7.52%
TOTAL ASSETS
Total Short-Term Assets	$129.6M	$150.2M	$183.3M
Total Long-Term Assets	$22.03M	$22.35M	$24.01M
Total Assets	$151.7M	$172.5M	$207.3M
YoY Change	-35.42%	-16.77%	-24.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.57M	$9.500M	$3.534M
YoY Change	163.21%	168.82%	50.7%
Accrued Expenses	$3.237M	$7.500M	$4.096M
YoY Change	41.97%	83.11%	25.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.20M	$17.41M	$8.308M
YoY Change	100.98%	109.61%	31.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$197.0K
YoY Change	-100.0%	-100.0%	1.55%
Total Long-Term Liabilities	$0.00	$0.00	$197.0K
YoY Change	-100.0%	-100.0%	1.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.20M	$17.41M	$8.308M
Total Long-Term Liabilities	$0.00	$0.00	$197.0K
Total Liabilities	$14.20M	$17.41M	$8.567M
YoY Change	94.59%	103.27%	28.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$380.8M	-$359.9M	-$264.4M
YoY Change	34.27%	36.12%	36.92%
Common Stock	$42.00K	$42.00K	$40.00K
YoY Change	0.0%	5.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$137.5M	$155.1M	$198.7M
YoY Change
Total Liabilities & Shareholders Equity	$151.7M	$172.5M	$207.3M
YoY Change	-35.42%	-16.77%	-24.42%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$20.92M	-$25.65M	-$20.26M
YoY Change	9.33%	26.63%	111.85%
Depreciation, Depletion And Amortization	$356.0K	$273.0K	$181.0K
YoY Change	-8.48%	50.83%	-14.62%
Cash From Operating Activities	-$22.32M	-$26.50M	-$21.55M
YoY Change	4.67%	22.97%	45.96%
INVESTING ACTIVITIES
Capital Expenditures	$41.00K	$0.00	-$1.156M
YoY Change	-112.24%	-100.0%	-94.76%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$41.00K	$0.00	-$1.156M
YoY Change	-112.24%	-100.0%	-94.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.143M	400.0K	136.0K
YoY Change	-97.59%	194.12%	81.33%
NET CHANGE
Cash From Operating Activities	-22.32M	-26.50M	-21.55M
Cash From Investing Activities	-41.00K	0.000	-1.156M
Cash From Financing Activities	1.143M	400.0K	136.0K
Net Change In Cash	-21.21M	-26.10M	-22.57M
YoY Change	-180.5%	15.64%	-38.55%
FREE CASH FLOW
Cash From Operating Activities	-$22.32M	-$26.50M	-$21.55M
Capital Expenditures	$41.00K	$0.00	-$1.156M
Free Cash Flow	-$22.36M	-$26.50M	-$20.39M
YoY Change	6.54%	29.94%	-380.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42129798
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42129798
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41735557
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41735557
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	0	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	119000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-29959
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1911336
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6801 N. Capital of Texas Highway, Building 1; Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78731
	dei	City Area Code CityAreaCode	512
	dei	Local Phone Number LocalPhoneNumber	501-2444
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	SAVA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42174062
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142350000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201015000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7834000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10211000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	150184000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	211226000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	122000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22077000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22864000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	268000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	622000	usd
CY2023Q3	us-gaap	Assets Assets	172529000	usd
CY2022Q4	us-gaap	Assets Assets	234834000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9492000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4017000	usd
CY2023Q3	sava	Accrued Development Expense Current AccruedDevelopmentExpenseCurrent	7344000	usd
CY2022Q4	sava	Accrued Development Expense Current AccruedDevelopmentExpenseCurrent	2280000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	187000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	170000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	104000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	391000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	492000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17414000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7063000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	197000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	17414000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7295000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	42000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	514923000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	511049000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359850000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283552000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	155115000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	227539000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	172529000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	234834000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23603000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18526000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70692000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50380000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4276000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2819000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12476000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8703000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	27879000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	21345000	usd
	us-gaap	Operating Expenses OperatingExpenses	83168000	usd
	us-gaap	Operating Expenses OperatingExpenses	59083000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-27879000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21345000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83168000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59083000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2005000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	878000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6254000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1223000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	223000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	210000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	616000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	748000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20257000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57112000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42002000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40050000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41845000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40009000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	253915000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	211000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17527000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	237094000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	119000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-19328000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	218370000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	-0	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	136000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20257000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	198719000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	227539000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24271000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	204005000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	889000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-26376000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	179353000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	464000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	155115000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57112000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2457000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1450000	usd
	us-gaap	Depreciation Depreciation	817000	usd
	us-gaap	Depreciation Depreciation	533000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	357000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	379000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2377000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2790000	usd
	sava	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	17000	usd
	sava	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	6000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5815000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3592000	usd
	sava	Increase Decrease In Development Expense IncreaseDecreaseInDevelopmentExpense	5064000	usd
	sava	Increase Decrease In Development Expense IncreaseDecreaseInDevelopmentExpense	1293000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	17000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1717000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-298000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-212000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59709000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56194000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	373000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3047000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-373000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3047000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1417000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	466000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1417000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	466000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-58665000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-58775000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	201015000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	233437000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	142350000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	174662000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates and assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q3	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	0	usd
CY2022Q3	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	400000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	900000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20257000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57112000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42002000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40050000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41845000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40009000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22077000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22864000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	273000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	181000	usd
	us-gaap	Depreciation Depreciation	817000	usd
	us-gaap	Depreciation Depreciation	533000	usd
	sava	Prepaid Expenses And Other Current Assets Text Bock PrepaidExpensesAndOtherCurrentAssetsTextBock	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid expenses and other current assets at <em style="font: inherit;"> September 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em> consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,136</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">874</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,224</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,285</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">189</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">160</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,834</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,211</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1136000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	874000	usd
CY2023Q3	us-gaap	Deposit Contracts Assets DepositContractsAssets	5224000	usd
CY2022Q4	us-gaap	Deposit Contracts Assets DepositContractsAssets	9177000	usd
CY2023Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	1285000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	189000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	160000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7834000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10211000	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	583000	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	620000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1699000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1780000	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	360000	usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	410000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1083000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1032000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	223000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	210000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	616000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	748000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24094000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24064000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2017000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1200000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1346000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1343000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1078000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	721000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	268000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	622000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	119000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	357000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	379000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	97000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	167000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	268000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2529448
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	132000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	495299
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7142
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2159007
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M18D
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8000000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	214124
CY2023Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	464000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	495299
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1417000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	949000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	469000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2457000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1450000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	0	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	41000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	24000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	123000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	0	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	41000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	24000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	124000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em> Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, the Company <em style="font: inherit;"> may </em>become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA, and <em style="font: inherit;"> may </em>receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company. <em style="font: inherit;">No</em> information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, <em style="font: inherit;">no</em> accrual for these matters has been recorded within the condensed consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Government Investigations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. <em style="font: inherit;">No</em> government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. <em style="font: inherit;">No</em> government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em>four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company’s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs’ claims against defendant Nadav Friedmann, PhD, MD, our former Chief Medical Officer and a Company director, who is now deceased, but otherwise denied defendants’ motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company’s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant’s alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since <em style="font: inherit;"> November 4, 2021, </em>four additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, one in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the three federal court actions were consolidated into a single action.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company’s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023. </em>Defendants’ motion to dismiss remains pending. Although the plaintiffs in this derivative case do <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
sava-20230930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
sava-20230930_def.xml	Edgar Link	unprocessable
sava-20230930_cal.xml	Edgar Link	unprocessable
0001437749-23-030502-index-headers.html	Edgar Link	pending
0001437749-23-030502-index.html	Edgar Link	pending
0001437749-23-030502.txt	Edgar Link	pending
0001437749-23-030502-xbrl.zip	Edgar Link	pending
a03.jpg	Edgar Link	pending
a04.jpg	Edgar Link	pending
a1.jpg	Edgar Link	pending
cass01.jpg	Edgar Link	pending
cass02.jpg	Edgar Link	pending
chart_2.jpg	Edgar Link	pending
ex_566477.htm	Edgar Link	pending
ex_566478.htm	Edgar Link	pending
ex_566479.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sava-20230930.xsd	Edgar Link	pending
sava20230930_10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sava-20230930_pre.xml	Edgar Link	unprocessable
sava20230930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SAVA
CASSAVA SCIENCES INC Stock $sava

2023 Q4 Form 10-Q Financial Statement

#000143774923030502 Filed on November 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SAVA CASSAVA SCIENCES INC Stock $sava

2023 Q4 Form 10-Q Financial Statement

#000143774923030502 Filed on November 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SAVA
CASSAVA SCIENCES INC Stock $sava